Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert R Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen K Sandhu, M Neil Reaume, David W Pook, Scott A North, Gavin M Marx, Anthony Joshua, Lisa Horvath, Ray McDermott, Simon Chowdhury, Kim N Chi, Alison Y Zhang, Martin R Stockler, Ian D Davis, Christopher J Sweeney
{"title":"Enzalutamide作为转移性激素敏感性前列腺癌的标准一线治疗:ENZAMET试验(ANZUP 1304)的简明语言总结","authors":"Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert R Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen K Sandhu, M Neil Reaume, David W Pook, Scott A North, Gavin M Marx, Anthony Joshua, Lisa Horvath, Ray McDermott, Simon Chowdhury, Kim N Chi, Alison Y Zhang, Martin R Stockler, Ian D Davis, Christopher J Sweeney","doi":"10.1080/14796694.2024.2440277","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).\",\"authors\":\"Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert R Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen K Sandhu, M Neil Reaume, David W Pook, Scott A North, Gavin M Marx, Anthony Joshua, Lisa Horvath, Ray McDermott, Simon Chowdhury, Kim N Chi, Alison Y Zhang, Martin R Stockler, Ian D Davis, Christopher J Sweeney\",\"doi\":\"10.1080/14796694.2024.2440277\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2440277\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2440277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.